Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
about
Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxA Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVADevelopment of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsA global approach to HIV-1 vaccine development4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaquesThe March Toward Malaria VaccinesIdentification of targets of CD8⁺ T cell responses to malaria liver stages by genome-wide epitope profilingA novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicitySeasonal vaccination against malaria: a potential use for an imperfect malaria vaccine.Adenoviral vectors as novel vaccines for influenza.Novel viral vectored vaccines for the prevention of influenza.Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates.Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.Nonreplicating vectors in HIV vaccines.Development of replication-competent viral vectors for HIV vaccine delivery.A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain.Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route.The influence of delivery vectors on HIV vaccine efficacyPlasmodium vivax malaria vaccines: why are we where we are?Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposureTranslating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populationsT cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.Novel vaccine vectors for HIV-1.Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsA phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe.Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.Development of an in vitro assay and demonstration of Plasmodium berghei liver-stage inhibition by TRAP-specific CD8+ T cellsCentralized Consensus Hemagglutinin Genes Induce Protective Immunity against H1, H3 and H5 Influenza Viruses.Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice
P2860
Q24273364-94675FA7-A79B-47BF-A080-AD7EE8E2EBB7Q24289279-D6A783C7-01D5-4864-840C-A92A5FAFA5B0Q26782083-532E5954-D165-48B5-AD09-4D110175B27EQ27024614-1D42977E-3529-45EE-9389-3B4423EC89B2Q27314155-D9DFF502-6BF1-4155-B57A-946B37C20CEDQ28084325-745631E6-0DD3-4870-8ABF-FC46B8AD5112Q28704543-024DF012-B2ED-4460-AF80-5FB31EB4FE36Q28727030-DEAD05A8-DF85-4878-9E5B-EA6807B25AD6Q30234589-358E7B5D-1646-497A-9943-7D08B40145D6Q30370445-BE314EA1-6A76-4669-929C-2B791D864B52Q30418570-CD32890F-BF13-4FDB-AED5-D55DB4A3BCAEQ33577093-D1177683-3510-48C2-BE28-1E387BA0FCB4Q33586992-541C587A-0314-4EFA-A576-6FF5861F0ED8Q33601808-B280CEE8-6912-4B33-88E7-3D8A04D29847Q33693891-84D8315C-5F67-4110-99CE-E3EC470FF7F7Q33694226-10CBC92F-A3C7-403A-84D4-10E75F328EE1Q33724960-393D36E1-EE24-4A67-BC21-9D7FA5E343DCQ33743457-C751F97E-966B-4BFA-98D6-DE1008793EEDQ33779750-1DB70EE5-2E7E-4B8A-B306-E46685881E10Q33798074-1FDCE843-97BB-46DF-A58A-837184446D23Q33875160-805758DC-D030-49CE-884E-FB106C8D3B46Q34072792-375E34A5-C1C2-4D93-AD94-53C914343920Q34077543-8D4F617A-981A-4A27-A9C5-09CB9663A66FQ34170071-71E81912-8147-41DC-8C76-6DB482044EC8Q34257253-BF3D7D19-68B2-47A6-B49E-630CD3F99637Q34301461-3DB725B3-B60C-41F5-8212-B7CF7DF937F5Q34416263-8921E358-3D0E-42AB-B965-437247F421F2Q34437167-1DBD8807-F49D-4DC7-9C43-B216635EE00BQ34541191-D334C605-7633-4347-B0BC-5033D56B8E8BQ34634002-01655AD8-0280-4D65-8847-118D1D422AC1Q34734075-6BD672D5-DF08-4B63-A789-F3E30B9B6D7EQ34792326-64B19DAA-E53B-4B5A-B9E0-80F9F27022FDQ34991437-F65E83A3-86D3-4CF8-909D-0664D1C33E47Q35091556-90D72E9E-5592-4691-AA26-73D96D9AE6C3Q35163318-29C019AD-FBBC-442A-8C6C-CFA297FD7242Q35231780-E5234DCF-933A-4341-B08A-DB49A0997F3BQ35808262-3E3B12E6-3907-4D58-8B4F-F539E431C78EQ36192765-4EC92AE9-87A9-43D0-A2F8-297027629505Q36225504-BE6EA1B5-90AF-41BD-B4BF-EA62161A6F18Q36291682-3BE426E0-AC74-4A87-A69F-3DE363945CC0
P2860
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Clinical assessment of a recom ...... : a potent new vaccine vector.
@ast
Clinical assessment of a recom ...... : a potent new vaccine vector.
@en
type
label
Clinical assessment of a recom ...... : a potent new vaccine vector.
@ast
Clinical assessment of a recom ...... : a potent new vaccine vector.
@en
prefLabel
Clinical assessment of a recom ...... : a potent new vaccine vector.
@ast
Clinical assessment of a recom ...... : a potent new vaccine vector.
@en
P2093
P2860
P50
P356
P1476
Clinical assessment of a recom ...... : a potent new vaccine vector.
@en
P2093
Alfredo Nicosia
Alison M Lawrie
Anna L Goodman
Antonella Folgori
Christopher J A Duncan
Claire Hutchings
Eleanor Berrie
Geraldine A O'Hara
Ian D Poulton
Laura Andrews
P2860
P304
P356
10.1093/INFDIS/JIR850
P407
P50
P577
2012-01-24T00:00:00Z